4594.T实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 14:15):

Stats
今日成交量	1.39M
平均成交量	848 905
市值	4.24B
EPS	¥0 ( 2024-02-09 )
下一个收益日期	( ¥0 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-3.14
ATR14	¥0.504 (0.83%)

音量相关性

長: -0.23 (neutral)

短: 0.00 (neutral)

Signal:(47.048) Neutral

BrightPath 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

BrightPath 相关性 - 货币/商品

0.26
( neutral )

-0.10
( neutral )

0.33
( neutral )

0.10
( neutral )

0.86
( strong )

-0.16
( neutral )

BrightPath 财务报表

Annual	2022
营收:	¥5.28M
毛利润:	¥3.39M (64.11 %)
EPS:	¥-24.90

FY	2022
营收:	¥5.28M
毛利润:	¥3.39M (64.11 %)
EPS:	¥-24.90

FY	2022
营收:	¥15.41M
毛利润:	¥12.09M (78.47 %)
EPS:	¥-28.55

FY	2021
营收:	¥2.50M
毛利润:	¥1.36M (54.27 %)
EPS:	¥-36.14

Financial Reports:

No articles found.

BrightPath

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.